Announcement based on the procedures for acquisition or disposal of assets

FDA Clearance of OBI-3424 IND Application for A Phase I/II Study Targeting AKR1C3 Solid Tumors

OBI Pharma Inc. to attend Credit Suisse Asian Investment Conference

Announcement on the Change of Chief Financial Officer

OBI Pharma’s Board of Directors approves the announcement of the Company’s 2017 individual and consolidated financial statements

The board of directors have resolved 2017 not to distribute dividends

The Board of Directors resolved to hold 2018 Annual General Meeting

Clarification on the news articles by Commercial Times, United Daily, etc.

FDA Clearance of IND Application for A Phase 1 Study of A Monoclonal Antibody Cancer Immunotherapy (OBI-888)

Shilin District Court deny OBI's request to submit the case for trial